Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Travere Therapeutics
Biotech
Travere scales Everest with $1.1B deal for BTK inhibitor
Travere has set its sights on Everest's therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic.
Will Maddox
Jun 2, 2026 10:30am
Midsize biotechs form coalition to fight against MFN policy
Feb 25, 2026 1:05pm
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
May 1, 2025 10:59am
Travere fails to beat off-label blood pressure drug in phase 3
May 2, 2023 7:00am
FDA’s liver safety request set to delay decision on Travere drug
Oct 14, 2022 10:05am
Vifor doles out $55M upfront to license Travere's asset
Sep 16, 2021 11:41am
